Mubritinib
From Self-sufficiency
File:Mubritinib structure.png | |
Systematic (IUPAC) name | |
---|---|
1-(4-{4-[(2-{(E)-2-[4-(trifluoromethyl)phenyl]ethenyl}-1,3-oxazol-4-yl)methoxy]phenyl}butyl)-1H-1,2,3-triazole | |
Clinical data | |
Routes of administration | Oral |
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | 366017-09-6 |
ATC code | none |
PubChem | CID 6444692 |
ChemSpider | 4948554 |
Chemical data | |
Formula | C25H23F3N4O2 |
Molar mass | 468.47 g/mol[[Script error: No such module "String".]] |
Script error: No such module "collapsible list". |
Mubritinib (TAK-165) is a protein kinase inhibitor which was under development by Takeda for the treatment of cancer.[1][2][3] It completed phase I clinical trials but appears to have been discontinued, as no new information on the drug has surfaced since December 2008.[4]
Synthesis
See also
References
Cite error: Invalid <references>
tag;
parameter "group" is allowed only.
<references />
, or <references group="..." />
- ↑ McCormick, Frank; Doriano Fabbro (2005). Protein Tyrosine Kinases: From Inhibitors to Useful Drugs (Cancer Drug Discovery and Development). Totowa, NJ: Humana Press. ISBN 1-58829-384-X.
- ↑ Mitscher, Lester A.; Lednicer, Daniel (1977). The organic chemistry of drug synthesis. New York: Wiley. ISBN 0-470-10750-2.
- ↑ Lednicer, Daniel (2008). Strategies for Organic Drug Synthesis and Design. New York: Wiley-Interscience. ISBN 0-470-19039-6.
- ↑ "Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2 - Full Text View - ClinicalTrials.gov".
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- 2Fix
- Antineoplastic drugs
- Oxazoles
- Triazoles
- CS1 maint: Multiple names: authors list